Please login to the form below

Not currently logged in


This page shows the latest leukaemia news and features for those working in and with pharma, biotech and healthcare.

Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

Allogene raises $324m from record-breaking IPO for off-the shelf CAR-Ts

It already has one AlloCAR candidate (UCART19) in phase 1 development for the treatment of relapsed/refractory acute lymphoblastic leukaemia (ALL), and results from the trial could be revealed as early

Latest news

More from news
Approximately 78 fully matching, plus 366 partially matching documents found.

Latest Intelligence

  • Made in China Made in China

    Novartis’leukaemia treatment Glivec.

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    The field is marching on rapidly. Studies of checkpoint inhibitors are now taking place in less common forms of cancer with greater unmet needs, such as gastric cancer, acute myelocytic leukaemia ... antigen receptor T-cell (CAR-T) therapies from

  • No incentive for a cure No incentive for a cure

    These include Kymriah, the pioneering CAR-T cell therapy from Novartis, which demonstrated a remarkable 83% remission rate in children and young adults with B-cell precursor acute lymphoblastic leukaemia.

  • Deal Watch January 2018

    leukaemia (ALL), Juno's share price had been in the low $20s for several months.

  • The tipping point The tipping point

    In 2016 alone, there were approximately 30 oncology drugs in late stage development for breast cancer, leukaemia, lung cancer and ovarian cancer.

More from intelligence
Approximately 1 fully matching, plus 42 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 12 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company Conferences, Events and Exhibition Stands is one of the UK’s leading event and exhibition agencies, specialising in healthcare. We understand your communication goals, whether...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...